Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PALATIN TECHNOLOGIES, INC.

(PTN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Palatin Technologies, Inc.
Palatin Technologies, Inc. (Palatin), is a biopharmaceutical company. Palatin is focused on developing medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Palatin product candidates are targeted receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. The melanocortin receptor (MCr) system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. The natriuretic peptide receptor (NPR) system regulates cardiovascular functions and tissue homeostasis, and therapeutic agents modulating this system have potential to treat cardiovascular and fibrotic diseases. Palatin lead product includes Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Its other product line includes PL9643 for dry eye disease and anti-inflammatory ocular indications and Oral PL8177 for inflammatory bowel diseases.
Sales per Business
20202021Delta
Melanocortin and Natriuretic Peptide Receptor Systems0.12100%---
USD in Million
Sales per region
20202021Delta
United States0.12100%---
USD in Million
Managers
Name Title Age Since
Carl Spana, Dr. Director 58 1996
Stephen T. Wills COO, CFO, Secretary, Treasurer & Executive VP 64 1997
Michael B. Raizman, Dr. Chief Medical Officer - 2021
John Dodd, Dr. Senior Vice President-Preclinical Development - -
John K. A. Prendergast, Dr. Director 67 1996
Robert K. deVeer Independent Director 75 1998
Joseph Stanley Hull Independent Director 68 2005
Alan W. Dunton, Dr. Independent Director 67 2011
Arlene M. Morris Independent Director 69 2015
Anthony Manning Independent Director 59 2017
Members of the board
Name Title Age Since
John K. A. Prendergast, Dr. Director 67 1996
Carl Spana, Dr. Director 58 1996
Robert K. deVeer Independent Director 75 1998
Joseph Stanley Hull Independent Director 68 2005
Alan W. Dunton, Dr. Independent Director 67 2011
Arlene M. Morris Independent Director 69 2015
Anthony Manning Independent Director 59 2017
Shareholders
NameEquities%
The Vanguard Group, Inc. 9,415,677 4.07%
Carl Spana 8,552,677 3.70%
Stephen T. Wills 7,640,464 3.30%
QVT Financial LP 4,296,847 1.86%
BlackRock Fund Advisors 2,954,943 1.28%
Alyeska Investment Group LP 2,385,321 1.03%
Baker Bros. Advisors LP 2,050,000 0.89%
ClariVest Asset Management LLC 1,712,000 0.74%
Geode Capital Management LLC 1,651,856 0.71%
John K. A. Prendergast 1,361,683 0.59%
Company contact information
Palatin Technologies, Inc.
Cedar Brook Corporate Center
4-B Cedar Brook Drive
Cranbury, NJ 08512

Phone : +1.609.495.2200
Fax : +1.609.495.2202
Web : http://www.palatin.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Palatin Technologies, Inc.